ABIVAX
Clinical-stage biotech developing therapeutics for chronic inflammatory diseases.
ABVX | PA
Overview
Corporate Details
- ISIN(s):
- FR0012333284 (+1 more)
- LEI:
- 969500D8TMNB184OJU95
- Country:
- France
- Address:
- 7 BOULEVARD HAUSSMANN, 75009 PARIS
- Website:
- https://www.abivax.com
- Sector:
- Manufacturing
Description
Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-06-10 18:00 |
Abivax releases the results of its June 9, 2022 ordinary annual and extraordina…
|
English | 6.1 KB | ||
| 2022-06-01 08:00 |
Abivax publie les résultats de l’étude de phase 2a d’obefazimod (ABX464) dans l…
|
French | 251.0 KB | ||
| 2022-06-01 08:00 |
Abivax phase 2a study results of obefazimod (ABX464) in rheumatoid arthritis pu…
|
English | 19.7 KB | ||
| 2022-05-24 18:00 |
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits …
|
French | 248.4 KB | ||
| 2022-05-18 18:00 |
Abivax annonce son assemblée générale mixte le 9 juin 2022 et la mise à disposi…
|
French | 143.7 KB | ||
| 2022-05-18 18:00 |
ABIVAX: Abivax announces annual ordinary and extraordinary general meeting on J…
|
English | 6.7 KB | ||
| 2022-04-28 18:00 |
Abivax met à disposition son Document d'Enregistrement Universel 2022
|
French | 148.1 KB | ||
| 2022-04-28 18:00 |
Abivax publishes Universal Registration Document 2022 'Document d'Enregistremen…
|
English | 9.7 KB | ||
| 2022-04-28 11:36 |
URD Abivax 2022
|
French | 18.8 MB | ||
| 2022-04-26 18:00 |
ABIVAX: Nombre d'actions composant le capital social et nombre total de droits …
|
French | 247.0 KB | ||
| 2022-04-06 18:00 |
Abivax annonce d'excellents résultats d'efficacité et de tolérance après un an …
|
French | 238.2 KB | ||
| 2022-04-06 18:00 |
Abivax reports excellent one-year efficacy and safety data of ABX464 phase 2b m…
|
English | 24.0 KB | ||
| 2022-03-17 18:00 |
ABIVAX: Nombre d'actions composant le capital social et nombre total de droits …
|
French | 248.0 KB | ||
| 2022-03-16 18:00 |
Abivax : Résultats annuels 2021 et point d'avancement sur l'activité
|
French | 337.7 KB | ||
| 2022-03-16 18:00 |
Abivax reports 2021 financial results and operations update
|
English | 50.1 KB |
Automate Your Workflow. Get a real-time feed of all ABIVAX filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ABIVAX
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ABIVAX via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-11 | N/A | Other | Buy | 319,107 | N/A |
| 2024-03-01 | N/A | Other | Buy | 7,000 | 91,557.90 EUR |
| 2023-12-19 | N/A | Other | Sell | 50,000 | 482,500.00 EUR |
| 2023-12-11 | N/A | Other | Sell | 2,062 | 19,382.80 EUR |
| 2023-11-13 | N/A | Other | Buy | 4 | 39.84 EUR |
| 2023-07-13 | N/A | Other | Sell | 192,781 | 3,101,480.01 EUR |
| 2023-03-27 | N/A | Other | Other | 38,461 | 249,996.50 EUR |
| 2023-02-27 | N/A | Other | Other | 1,535,000 | 9,977,500.00 EUR |
Peer Companies
